To our #sitepartners on the front lines, from all of us at Biorasi, thank you for everything you do to bring critical treatments to patients as we face #COVID19 together.
Unflattening the Curve: Minimize the Impact to Patients Who Depend on Your Successful Clinical Trial
In this time of uncertainty caused by the COVID-19 pandemic, the importance of delivering new treatments to patients as quickly as possible has never been more vital. Without a proactive and comprehensive strategy in place to manage clinical trials over the coming weeks and maybe months, consequences may be severe –especially for those that need the treatment the most.
Digital technology’s presence in the healthcare industry continues to grow, expanding across diagnostic and therapeutic treatments in precision medicine. Biorasi was on-site to witness these advancements and innovations at this year’s Molecular Med Tri-Con.
In observance of Rare Disease Day 2020, Biorasi, LLC held a company-wide event and fundraiser to raise awareness for Angelman Syndrome. The company contributed over $4,000 to the Foundation for Angelman Syndrome Therapeutics. Read more about the highlights of this event >>
The Evolution of Digital Therapeutics and the Need for Clinical Evidence: Lessons Learned from DTx West 2020
With digital therapeutics experiencing an evolution, Biorasi was on hand at DTx West 2020 to highlight the importance of evidence as a differentiator in clinical trials. Read more about our event experience >>
Biorasi, LLC and its Board of Directors are proud to announce the appointment of Chris O’Brien to the position of Chief Executive Officer (CEO). O’Brien will assume day-to-day leadership of Company operations, working closely with the Biorasi leadership team to deliver cutting-edge solutions for clinical research project management.
When stem cell industry innovators from across the globe congregated in Miami at the end of January 2020 to discuss the current state and future expectations of the regenerative medicine industry, Biorasi had more than one reason to be excited about the event. Read the full article for highlights >>
A team from Biorasi was at ASN Kidney Week 2019. Breakthrough research and standout presentations marked this year’s @ASNKidney Week. Check out our report for the full scoop.
A team from Biorasi joined more than 900 leaders from the FDA, NIH and the pharma and bio-pharma industries for the National Organization for Rare Disorders (NORD) & Orphan Products Breakthrough Summit. Throughout two packed days of keynotes, breakout sessions and panel discussions, we gained valuable insight into the most urgent rare disease topics. Read about the a few takeaways from the event in this article.
As digital therapeutics are integrated into every aspect of the healthcare landscape, patients, payers, and providers are seeing an increasingly complex set of software-driven therapy options reaching the market. This rapidly expanding field has enormous potential but faces challenges at every stage, from design to patient perception. Focusing on the clinical trial stage, how does the trial of a digital therapeutic compare to that of a pharmaceutical? What are the specific challenges of running a digital therapeutics clinical trial, and how can sponsors adapt their approach for the highest chance of success?
In my previous article, I explained the types, causes and symptoms of Acute Kidney Injury (AKI). Here, I’ll share how physicians treat and manage AKI, as well as what to expect. CRRT or intermittent hemodialysis? To treat AKI, nephrologists primarily use renal replacement therapy (RRT), which includes intermittent hemodialysis, peritoneal hemodialysis, various forms of CRRT, and “hybrid” therapies such as prolonged intermittent renal replacement therapy (PIRRT) or sustained low-efficiency hemodialysis (SLED). A few clinical trials are taking a look at CRRT and intermittent hemodialysis under different conditions.
What is AKI? AKI is a sudden, reversible decline in the kidney’s glomerular filtration rate (GFR); in other words, its ability to filter metabolic waste. This kidney damage causes an elevation of serum urea and creatinine, which affects the body's ability to function properly. Most AKI cases are reversible. However, it's important to treat AKI as early as possible to avoid its progression to chronic kidney disease or kidney failure.